Skye Bioscience, Inc.
General ticker "SKYE" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $44.7M (TTM average)
Skye Bioscience, Inc. does not follow the US Stock Market performance with the rate: -26.3%.
Estimated limits based on current volatility of 3.6%: low 1.51$, high 1.62$
Factors to consider:
- Total employees count: 12 (-25.0%) as of 2025
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Limited operating history, Going concern doubt, Depend on nimacimab development, Third-party risks, Need substantial additional funding
- Current price 57.7% below estimated low
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [3.67$, 12.92$]
- 2026-12-31 to 2027-12-31 estimated range: [2.73$, 9.52$]
Financial Metrics affecting the SKYE estimates:
- Negative: with PPE of -1.1 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Negative: negative Net income
- Negative: 0 < Industry inventory ratio change (median), % of 0
- Negative: negative Industry operating cash flow (median)
- Positive: 69.38 < Shareholder equity ratio, % of 70.72 <= 81.92
- Positive: Interest expense per share per price, % of 0 <= 0
Short-term SKYE quotes
Long-term SKYE plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $6.23MM | $0.00MM |
| Operating Expenses | $34.74MM | $36.43MM | $58.16MM |
| Operating Income | $-34.74MM | $-30.19MM | $-58.16MM |
| Non-Operating Income | $-2.91MM | $3.64MM | $2.24MM |
| Interest Expense | $0.91MM | $0.97MM | $0.00MM |
| R&D Expense | $5.82MM | $18.70MM | $42.36MM |
| Income(Loss) | $-37.64MM | $-26.56MM | $-55.92MM |
| Taxes | $0.00MM | $0.01MM | $0.01MM |
| Net Income(Loss)* | $-37.64MM | $-26.57MM | $-55.92MM |
| Stockholders Equity | $-2.13MM | $68.15MM | $20.02MM |
| Assets | $11.94MM | $72.76MM | $28.31MM |
| Operating Cash Flow | $-13.95MM | $-25.24MM | $-43.06MM |
| Capital expenditure | $0.01MM | $1.60MM | $0.01MM |
| Investing Cash Flow | $6.60MM | $-0.25MM | $-19.50MM |
| Financing Cash Flow | $16.44MM | $83.56MM | $0.03MM |
| Earnings Per Share** | $-42.99 | $-5.83 | $-11.28 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.